Today

Agents

Chat

Arena

Discover

More

App

NeuroSense plans PrimeC new drug filing with Health Canada for ALS - NRSN News | Rallies

NeuroSense plans PrimeC new drug filing with Health Canada for ALS

NRSN•2026-07-22

Planned Health Canada filing for PrimeC

NeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting.

The submission package includes Phase 2b PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037).

Related News

PBF Energy Inc <PBF.N>: Bofa Global Research raises price objective to $53 from $30

PBF•2026-07-22

Highway Holdings signs LOI with Huahu for 57%-owned Wowtiger energy storage joint venture

HIHO•2026-07-22

K&S updates financial calendar with fiscal Q3 2026 results release, conference call

KLIC

•

2026-07-22

Ferrovial renews EUR 1.5 billion euro commercial paper program

FER•2026-07-22

Suncor Energy Inc (Canada) <SU.TO>: BofA Global Research raises price objective to C$94 from C$72

SU•2026-07-22